RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31
Cartesian Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$6.08−0.19 (-3.03%)
Close on Oct 19, 2026
- Market cap
- $181.55M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Cartesian Therapeutics has not reported a dividend
No dividend per share appears in Cartesian Therapeutics's annual filings since fiscal 2013.